Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis.
暂无分享,去创建一个
M. Mayr | Y. Suárez | C. Fernández-Hernando | N. Rotllan | D. Ford | Á. Baldán | Xinbo Zhang | A. Canfrán-Duque | N. Arias | Paramita Pati | Jack M. Moen | Nathan L. Price
[1] S. Blankenberg,et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. , 2018, European heart journal.
[2] Rachel C. Bandler,et al. microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[3] M. Mayr,et al. MicroRNAs in Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.
[4] A. Näär,et al. MicroRNA-33 Regulates the Innate Immune Response via ATP Binding Cassette Transporter-mediated Remodeling of Membrane Microdomains * , 2016, The Journal of Biological Chemistry.
[5] P. Loke,et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. , 2015, The Journal of clinical investigation.
[6] Mary-Ellen Harper,et al. Macrophage mitochondrial energy status regulates cholesterol efflux and is enhanced by anti‐miR33 in atherosclerosis , 2015, Circulation research.
[7] Takeshi Kimura,et al. Abstract 13545: MicroRNA-33b Knock-in Mice for an Intron of Sterol Regulatory Element-Binding Factor 1 (Srebf1) Exhibit Reduced HDL-C in vivo , 2014 .
[8] D. Rader,et al. HDL and cardiovascular disease , 2014, The Lancet.
[9] M. Mayr,et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice , 2014, EMBO molecular medicine.
[10] Á. Baldán,et al. Control of Very Low-Density Lipoprotein Secretion by N-Ethylmaleimide-Sensitive Factor and miR-33 , 2014, Circulation research.
[11] D. Rader,et al. Future of cholesteryl ester transfer protein inhibitors. , 2014, Annual review of medicine.
[12] Takeshi Kimura,et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice , 2013, Nature Communications.
[13] S. Kauppinen,et al. Pharmacological Inhibition of a MicroRNA Family in Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR , 2013, Science Translational Medicine.
[14] J. Chiang,et al. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7α‐hydroxylase/steroid response element‐binding protein 2/microRNA‐33a axis in mice , 2013, Hepatology.
[15] G. Kroemer,et al. Mechanisms of apoptotic phosphatidylserine exposure , 2013, Cell Research.
[16] C. Ramírez,et al. Therapeutic Silencing of MicroRNA-33 Inhibits the Progression of Atherosclerosis in Ldlr−/− Mice—Brief Report , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[17] R. de Cabo,et al. A Regulatory Role for MicroRNA 33* in Controlling Lipid Metabolism Gene Expression , 2013, Molecular and Cellular Biology.
[18] A. Lusis,et al. Anti-miR-33 Therapy Does Not Alter the Progression of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[19] L. Goedeke,et al. MicroRNAs in metabolic disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[20] Takeshi Kimura,et al. MicroRNA-33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE−/− Mice , 2012, Journal of the American Heart Association.
[21] F. Suchy,et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity , 2012, EMBO molecular medicine.
[22] Zahi A Fayad,et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.
[23] Aaron N. Chang,et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. , 2011, The Journal of clinical investigation.
[24] K. Moore,et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling , 2011, Proceedings of the National Academy of Sciences.
[25] K. Moore,et al. MicroRNAs in lipid metabolism , 2011, Current opinion in lipidology.
[26] Takeshi Kimura,et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo , 2010, Proceedings of the National Academy of Sciences.
[27] I. Gérin,et al. Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation* , 2010, The Journal of Biological Chemistry.
[28] Daniel S. Ory,et al. miR-33 links SREBP-2 induction to repression of sterol transporters , 2010, Proceedings of the National Academy of Sciences.
[29] T. Shioda,et al. MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis , 2010, Science.
[30] K. Moore,et al. MiR-33 Contributes to the Regulation of Cholesterol Homeostasis , 2010, Science.
[31] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[32] A. Tall,et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.
[33] M. Greenberg,et al. Oxidized phosphatidylserine–CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells , 2006, The Journal of experimental medicine.
[34] Roger A. Davis,et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .
[35] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[36] Joseph L Goldstein,et al. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.
[37] A. Shiratsuchi,et al. Essential role of phosphatidylserine externalization in apoptosing cell phagocytosis by macrophages. , 1998, Biochemical and biophysical research communications.
[38] Ryan E. Temel,et al. Inhibition of miR-33 a / b in non-human primates raises plasma HDL and lowers VLDL triglycerides , 2011 .
[39] Roger A. Davis,et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. , 2004, The Journal of clinical investigation.